• 1
    Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: GoldMR, SiegelJE, RussellJE, WeinsteinMC, editors. Cost-effectiveness in health and medicine. New York: Oxford University; 1996. p. 176213.
  • 2
    Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. Woden, Australia: Department of Health, Housing and Community Services; 1990.
  • 3
    Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993; 4: 44654.
  • 4
    Ontario Ministry of Health. Guidelines for preparation of economic analysis to be included in submission to Drug Programs Branch for listing in the Ontario Drug Benefit Formulary/Comparative Drug Index. Ontario: Ministry of Health; 1991.
  • 5
    Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 100510.
  • 6
    Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3: 38593.
  • 7
    Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 17189.
  • 8
    Reginster JY. The prevalence and burden of arthritis. Rheumatology (Oxford) 2002; 41 Suppl 1: 36.
  • 9
    Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004; 22: 112.
  • 10
    Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 2002; 14: 1216.
  • 11
    March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997; 11: 81734.
  • 12
    Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21: 82733.
  • 13
    Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000; 29: 30520.
  • 14
    Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996; 44: 4751.
  • 15
    Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 2005; 23: 24357.
  • 16
    Xie F, Thumboo J, Li SC. True difference or something else? Problems in cost of osteoarthritis studies. Semin Arthritis Rheum 2007; 37: 12732.
  • 17
    Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 34756.
  • 18
    Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003; 49: 6470.
  • 19
    Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002; 20: 50515.
  • 20
    Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 4606.
  • 21
    Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: GoldMR, SiegelJE, RussellJE, WeinsteinMC, editors. Cost-effectiveness in health and medicine. New York: Oxford University; 1996. p. 21435.
  • 22
    Human Development Report Office, UNDP. 2007/2008 report: economic performance. Consumer price index, average annual change in (%): 1990–2005. URL:
  • 23
    Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, et al. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making 2007; 27: 13850.
  • 24
    Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65: 117583.
  • 25
    Verstappen SM, Boonen A, Verkleij H, Bijlsma JW, Buskens E, Jacobs JW, for the Utrecht Rheumatoid Arthritis Cohort Study Group. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005; 64: 175460.
  • 26
    Merkesdal S, Ruof J, Huelsemann JL, Mittendorf T, Handelmann S, Mau W, et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the Health Economic Patient Questionnaire HEQ-RA and insurance claims data [published erratum appears in Arthritis Rheum 2005;53:624]. Arthritis Rheum 2005; 53: 23440.
  • 27
    Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a 2-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46: 23109.
  • 28
    Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford) 2004; 43: 137482.
  • 29
    Puolakka K, Kautiainen H, Pekurinen M, Mottonen T, Hannonen P, Korpela M, et al, for the FIN-RACo Trial Group. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006; 65: 899904.
  • 30
    Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first 3 years of disease. Arthritis Rheum 2001; 44: 52834.
  • 31
    Pentek M, Kobelt G, Czirjak L, Szekanecz Z, Poor G, Rojkovich B, et al. Costs of rheumatoid arthritis in Hungary. J Rheumatol 2007; 34: 1437.
  • 32
    Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004; 63: 395401.
  • 33
    Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000; 42: 58896.
  • 34
    McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 78190.
  • 35
    Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med 2006; 48: 13548.
  • 36
    Ruof J, Hulsemann JL, Mittendorf T, Handelmann S, der Schulenburg JM, Zeidler H, et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on health care payer's data sources. Ann Rheum Dis 2003; 62: 5449.
  • 37
    Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12-year study. J Rheumatol 1997; 24: 105160.
  • 38
    Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24: 438.
  • 39
    Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 116975.
  • 40
    Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006; 44: 30410.
  • 41
    Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ, et al, for the Western Consortium of Practicing Rheumatologists. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000; 27: 115663.
  • 42
    Osiri M, Maetzel A, Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a 1-year prospective cohort study in Thailand. J Rheumatol 2007; 34: 5763.
  • 43
    Soderlin MK, Kautiainen H, Jonsson D, Skogh T, Leirisalo-Repo M. The costs of early inflammatory joint disease: a population-based study in southern Sweden. Scand J Rheumatol 2003; 32: 21624.
  • 44
    Gupta S, Hawker GA, Laporte A, Croxford R, Coyte PC. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology (Oxford) 2005; 44: 15317.
  • 45
    Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol 2004; 22: 699706.
  • 46
    Woo J, Lau E, Lau CS, Lee P, Zhang J, Kwok T, et al. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs. Arthritis Rheum 2003; 49: 52634.
  • 47
    Xie F, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, et al. Direct and indirect costs of osteoarthritis in Singapore: a comparative study among multiethnic Asian patients with osteoarthritis. J Rheumatol 2007; 34: 16571.
  • 48
    CDC targets arthritis, a leading cause of disability. Public Health Rep 1999; 114: 102.
  • 49
    Koopmanschap MA, Rutten FF. The consequence of production loss or increased costs of production. Med Care 1996; 34 Suppl 12: DS5968.